Improving vaccine efficacy against malignant glioma

ABSTRACT The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

[1]  R. Lulla,et al.  Mutations in chromatin machinery and pediatric high-grade glioma , 2016, Science Advances.

[2]  D. Wainwright,et al.  Immunotherapy for cancer in the central nervous system: Current and future directions , 2015, Oncoimmunology.

[3]  L. Recht,et al.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. , 2015, Neuro-oncology.

[4]  T. Gajewski,et al.  The STING pathway and the T cell-inflamed tumor microenvironment. , 2015, Trends in immunology.

[5]  W. Wick,et al.  Mutant IDH1: An immunotherapeutic target in tumors , 2014, Oncoimmunology.

[6]  Simon C Watkins,et al.  STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[7]  A. Unterberg,et al.  SPONTANEOUS IMMUNE RESPONSES IN GBM PATIENTS AFTER COMPLETE TUMOR RESECTION ARE ASSOCIATED WITH AN IMPROVED SURVIVAL , 2014 .

[8]  A. Panigrahy,et al.  Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Stevanović,et al.  A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.

[10]  Katherine K. Matthews,et al.  Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. , 2014, Cancer research.

[11]  R. McLendon,et al.  EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma , 2014, PloS one.

[12]  Y. Cheng,et al.  Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.

[13]  M. Wiles,et al.  Generation of improved humanized mouse models for human infectious diseases , 2014, Journal of Immunological Methods.

[14]  Kay-Hooi Khoo,et al.  Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers , 2014, Proceedings of the National Academy of Sciences.

[15]  Susan M. Chang,et al.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.

[16]  J. Zimmer,et al.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.

[17]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[18]  J. Blay,et al.  Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. , 2013, Cancer research.

[19]  L. Liau,et al.  Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. , 2013, Anticancer research.

[20]  R. Kaur,et al.  Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages , 2013, Clinical Cancer Research.

[21]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[22]  D. Bigner,et al.  Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. , 2013, Drugs of the future.

[23]  C. Mathers,et al.  Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions , 2012, The Lancet.

[24]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[25]  Susan M. Chang,et al.  Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein , 2012, Clinical Cancer Research.

[26]  S. Phuphanich,et al.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.

[27]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. Thaci,et al.  Recent developments on immunotherapy for brain cancer , 2012, Expert opinion on emerging drugs.

[29]  B. O'neill,et al.  Glioblastoma survival in the United States before and during the temozolomide era , 2012, Journal of Neuro-Oncology.

[30]  T. Akaike,et al.  Regulation by mitochondrial superoxide and NADPH oxidase of cellular formation of nitrated cyclic GMP: potential implications for ROS signalling. , 2012, The Biochemical journal.

[31]  D. Männel,et al.  Humanized tumor mice—A new model to study and manipulate the immune response in advanced cancer therapy , 2011, International journal of cancer.

[32]  Yun-jie Wang,et al.  Increased transforming growth factor-β2 in epidermal growth factor receptor variant III-positive glioblastoma , 2011, Journal of Clinical Neuroscience.

[33]  B. Rini,et al.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. , 2011, Neuro-oncology.

[34]  Richard D Bruggeman,et al.  The detection of CMV pp65 and IE1 in glioblastoma multiforme , 2011, Journal of Neuro-Oncology.

[35]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Wishart,et al.  Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy , 2011, Journal of immunotherapy.

[37]  C. Rice,et al.  Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγ(null) humanized mice. , 2011, Blood.

[38]  R. McLendon,et al.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.

[39]  E. Benarroch.  Heat shock proteins , 2011, Neurology.

[40]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[41]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Lai-Xi Wang,et al.  Antibody recognition of a unique tumor-specific glycopeptide antigen , 2010, Proceedings of the National Academy of Sciences.

[43]  A. Dietz,et al.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. , 2010, Neuro-oncology.

[44]  C. Kramm,et al.  Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours , 2010, Pediatric blood & cancer.

[45]  S. Evans.  Clinical trial structures. , 2010, Journal of experimental stroke & translational medicine.

[46]  R. Grossman,et al.  HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors , 2010, Clinical Cancer Research.

[47]  R. McLendon,et al.  EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma , 2009, Brain pathology.

[48]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[49]  T. Gaiser,et al.  KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway , 2009, Neurobiology of Disease.

[50]  R. Weissleder,et al.  Genetically engineered T cells to target EGFRvIII expressing glioblastoma , 2009, Journal of Neuro-Oncology.

[51]  P. L. Poliani,et al.  NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties1 , 2009, The Journal of Immunology.

[52]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[53]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[54]  J. Nikawa,et al.  Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. , 2008, Oncology reports.

[55]  K. Aldape,et al.  Detection of human cytomegalovirus in different histological types of gliomas , 2008, Acta Neuropathologica.

[56]  R. McLendon,et al.  Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. , 2008, Neuro-oncology.

[57]  Harry Bartelink,et al.  Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas , 2007, Breast Cancer Research.

[58]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Masahiro Toda,et al.  Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients , 2007, International journal of cancer.

[60]  W. Hall,et al.  Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy , 2007, Journal of Neuro-Oncology.

[61]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[62]  K. Itoh,et al.  Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. , 2007, Oncology reports.

[63]  Jian Gang Zhang,et al.  Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics , 2007, Clinical Cancer Research.

[64]  G. Mckhann,et al.  Defective Receptor Expression and Dendritic Cell Differentiation of Monocytes in Glioblastomas , 2006, Neurosurgery.

[65]  M. Lesniak,et al.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. , 2006, Journal of neurosurgery.

[66]  M. Lesniak,et al.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. , 2006, Neuro-oncology.

[67]  S. Bay,et al.  Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression. , 2005, Cancer research.

[68]  I. Pollack,et al.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. , 2005, Neoplasia.

[69]  A. Kobata,et al.  Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours , 2005, Immunology and cell biology.

[70]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[71]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[72]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[73]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[74]  T. Kawase,et al.  Expression of a transcriptional factor, SOX6, in human gliomas , 2004, Brain Tumor Pathology.

[75]  K. Black,et al.  HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells , 2004, Cancer Research.

[76]  D. Xie,et al.  AIM-2: A Novel Tumor Antigen is Expressed and Presented by Human Glioma Cells , 2004, Journal of immunotherapy.

[77]  R. Binder,et al.  Essential role of CD91 in re-presentation of gp96-chaperoned peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Dichgans,et al.  MICA/NKG2D-mediated immunogene therapy of experimental gliomas. , 2003, Cancer research.

[79]  G. Kvalheim,et al.  A Protocol for Generation of Clinical Grade mRNA‐Transfected Monocyte‐Derived Dendritic Cells for Cancer Vaccines , 2003, Scandinavian journal of immunology.

[80]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[81]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[82]  A. Friedman,et al.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  P. Wernet,et al.  Clinical-Scale Generation of Dendritic Cells in a Closed System , 2003, Journal of immunotherapy.

[84]  C. Marosi,et al.  Survival and prognostic factors of patients with unresectable glioblastoma multiforme , 2003, Anti-cancer drugs.

[85]  C. Cobbs,et al.  Human cytomegalovirus infection and expression in human malignant glioma. , 2002, Cancer research.

[86]  Kris Thielemans,et al.  Generation of large numbers of dendritic cells in a closed system using Cell Factories. , 2002, Journal of immunological methods.

[87]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[88]  M. Mizuno,et al.  Dendritic cells pulsed with tumor extract–cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor , 2001, Cancer Immunology, Immunotherapy.

[89]  J. Moringlane,et al.  Expression of cancer testis genes in human brain tumors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  T. Cloughesy,et al.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. , 1999, Journal of neurosurgery.

[91]  Mihir S. Wagh,et al.  The Dual Nature of Specific Immunological Activity of Tumor-derived gp96 Preparations , 1999, The Journal of experimental medicine.

[92]  C. Chow,et al.  Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  Jean Kanitakis,et al.  Differential expression of the cancer associated antigens T (Thomsen-Friedenreich) and Tn to the skin in primary and metastatic carcinomas. , 1998, Journal of clinical pathology.

[94]  H. Poulsen,et al.  Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[96]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[97]  R. Flavell,et al.  Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. , 1995, Journal of immunology.

[98]  W. Paulus,et al.  Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. , 1995, The American journal of pathology.

[99]  K. Okumura,et al.  Selective expression of interleukin-10 gene within glioblastoma multiforme , 1994, Brain Research.

[100]  P. Srivastava,et al.  Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. Flavell,et al.  Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. , 1993, Journal of immunology.

[102]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[103]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[104]  S. Sell,et al.  Cancer-associated carbohydrates identified by monoclonal antibodies. , 1990, Human pathology.

[105]  R. Kerbel,et al.  Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. , 1987, Science.

[106]  P. Srivastava,et al.  Tumor rejection antigens of chemically induced sarcomas of inbred mice. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[107]  P. Stiff,et al.  Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A phase ii study by the illinois cancer council , 1985, Cancer.

[108]  R. Dinapoli,et al.  Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. , 1982, Cancer treatment reports.

[109]  Jill S Barnholtz-Sloan,et al.  Epidemiology of gliomas. , 2015, Cancer treatment and research.

[110]  L. Shultz,et al.  Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. , 2014, Methods in molecular biology.

[111]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[112]  Edith Schwamborn,et al.  Isolation and generation of clinical-grade dendritic cells using the CliniMACS system. , 2005, Methods in molecular medicine.

[113]  H. Sakahara,et al.  Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract , 2005, Journal of Cancer Research and Clinical Oncology.

[114]  A. Lawson,et al.  Artificial T-cell receptors. , 2003, Cytotherapy.

[115]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[116]  R. Eagan,et al.  Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  H. Bisel,et al.  Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumors. , 1981, Oncology.